Introduction: Portulaca oleracea is a common plant used in South Indian culinary; recently there is increase in research publication on various biological activities of the medicinal herb. The safety of the medicinal herb well accounted by its widespread accepted use of natives yet scientific evaluation on the safety of the herb is not reported. Aim To scientifically evaluate the toxicity profile of the pet-ether extract of Portulaca oleracea by standardized methods. Method A 24hour acute toxicity study followed by 14 day sub-acute toxicity study with serum haematological, biochemical and histopathological analysis's is evaluated in rodents. Result No observable serious side effects are recorded in acute and sub acute toxicity study for 0.5gm/kg and 1gm/kg pet-ether extract of Portulaca oleracea. There are statistically significant rising (p<0.01) in hemoglobin by 13.25%, 15.42% and 15.04% in Portulaca oleracea 0.5gm, 1gm, and 2gm/kg body weight respectively when compared to control 10.56%. Portulaca oleracea 2gm/kg dose administration for 14 days has revealed oxalate crystal deposits in the kidney. Conclusion The pet-ether extracts of Portulaca oleracea 0.5gm, 1gm, and 2gm/kg exhibited zero mortality rates in both acute and sub-acute toxicity studies and found to increase haemoglobin, total cholesterol levels in serum which can be seriously evaluated for further research.

Eletriptan is at the type of triptan medication suggested for the management of episodes of severe headache with or without aura. Piperine (1-piperoylpiperidine) is a pure alkaloid as well as the basic tanginess material from the pipli and peppercorn. There are signs that piperine inhibits Cytochrome P-450 enzymes and P-glycoprotein, rather than arouses, drug metabolism generally, thus increasing the bioavailability and effect of several medications. The analysis was undertaken to assess the results of Piperine on the pharmacokinetics of Eletriptan. Samples of blood were taken at different time points for example 0 (predose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0, 12, 24 hours post-treatment. The plasma concentration of Eletriptan was estimated with the HPLC procedure.  In our study Cmax, Tmax, AUC0-24 , AUC0-8, AUC%, AUMC0-24, AUMC0-8, t1/2, MRT0-24, MRT0-8 and Volume of distribution were increased by approximately 51.76%, 7.55%, 72.93%, 84.42%, 42.72%, 93.56%, 128.82%, 19.97%, 11.74%, 23.96% and 3% respectively, where as clearance decreased by 42.10% when eletriptan co-administered with piperine. In summary, the results obtained herein imply that Piperine is improving the bioavailability of Eletriptan by strengthening the exposure (AUC) of their Eletriptan when concomitantly administered by the oral route. The Piperine improved the oral bioavailability of eletriptan by inhibiting CYP3A and P-GP in rats. This observation indicates the possibility that the combo of piperine along with other CYP3A and P-GP double substrates can also enhance bioavailability.

No abstract